ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SNG Synairgen Plc

4.675
0.155 (3.43%)
25 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.155 3.43% 4.675 4.35 5.00 - 25,623 16:35:16
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.52 9.1M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.52p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.10 million. Synairgen has a price to earnings ratio (PE ratio) of -0.52.

Synairgen Share Discussion Threads

Showing 4826 to 4849 of 99175 messages
Chat Pages: Latest  199  198  197  196  195  194  193  192  191  190  189  188  Older
DateSubjectAuthorDiscuss
23/4/2020
12:01
Dovey21, 20 years for me but did time in the reserves prior to joining full time. Good luck to us both.
rafboy
23/4/2020
12:00
Ok I think I must have missed that bit as trying to move over my last 4 D shares
slinkyj
23/4/2020
11:59
From proactive interview a few weeks ago or one today.

Up she blows!

likya123
23/4/2020
11:59
From the you tube interview.
dovey21
23/4/2020
11:59
62p resistance- could easily break that today by a wide margin.
imjustdandy
23/4/2020
11:58
Nobby, are you aware of any simple testing for low IFN levels around eg home sputum /saliva testing ?
141jaffa
23/4/2020
11:58
Wow where was that info from Likya?
slinkyj
23/4/2020
11:58
I left 2013 (24 years) Eng Ops BZN..still with the MOD.
dovey21
23/4/2020
11:57
He also said "our time has come". This is their moment.
imjustdandy
23/4/2020
11:57
Our CEO just now!!!

You can never say that you never had all the clues....

"We have started the manufacturing process [devices for delivery of the drug to lungs and more drug products] and we have started to look down the supply chain to ensure we can provide millions of doses to people around the world"

This is the one and it's about to blow big!

likya123
23/4/2020
11:56
No left in 2001. Last job OC PMS at RAF ST Mawgan.
rafboy
23/4/2020
11:54
>>>Rafboy....still serving?
dovey21
23/4/2020
11:52
Yes, not a time to be selling is my personal view. I have added today and will be in for more when funds become available.
rafboy
23/4/2020
11:51
People in hospital start off with bad symptoms that get worse , from watching something on TV the other day there is a Goldilocks moment when people come in that if SNG was applied it would prevent the patient from going to ventilator stage. Let a see what the results say, but very confident this is the bio to be in right now. MMS caught up with the news yet lol
slinkyj
23/4/2020
11:49
Good interview. The home treatment approach would tie in with other advances coming on stream soon. Avacta should have a home test like a home pregnancy test where you use saliva on a stick and get the results in 10 mins. If you are an at risk person you can then start using SNG immediately. Hopefully, no need to go to hospital and recover quicker.

It does seem the best results for IFN treatment are when you start early. It is a concern that perhaps those being treated in hospital are already too infected to benefit and therefore SNG may need to start this more upstream trial.

It was good to hear they are planning ahead with manufacture and importantly thinking about supply chain materials.

Also good that they will keep the market updated with timings. Perhaps an RNS stating recruitment complete on Monday?

Overall upbeat, in his usual calm professional way. Although I thought he did look tired, which is understandable!

pdt
23/4/2020
11:40
HUGE! It's a Win-Win solution and treatment for patients and for the NHS/carers. Massive potential here post trial results.
dovey21
23/4/2020
11:38
Exactly, if this can be administered at home then the benefits to the patient and the NHS is beyond belief.
imjustdandy
23/4/2020
11:33
If the bullishness can hold off a bit I will have a small sum to invest on Monday hopefully. Then it can take off ;-) Seems promising. Why mention the home plans if not very confident something positive will be announced?
lauders
23/4/2020
11:25
Excellent interview from my point of view. The first major point is the home treatment where a trial is due to start soon from what he said. That greatly increases the potential market. And the second is that I interpreted from what he said that there could be approval on the back of the SG016 results. I have been saying that for awhile but I think he confirmed it tacitly. Also interesting that they will update the market with timings of the trial. We can look forward to those announcements.

Great stuff.

nobbygnome
23/4/2020
11:24
Do you think this could be put into a regular inhaler? I'm no biologist / pharmacist so anyone with knowledge I would love to hear?
slinkyj
23/4/2020
11:20
From lse board...

jack_allis

Today 01:05

Posts: 2,443

Price: 58.00

"SARS-CoV-2, despite the higher titre, *does not induce interferon secretion* and causes lower upregulation of proinflammatory cytokines than does SARS-CoV."



Emphasis in above quote is my own

Recommend (7)Report Post

Miggy007

Today 06:15

Posts: 186

Price: 58.00

Jack-allis - Great find, noted part of the conclusion to one of these reports, University of Texas:

Overall, our results indicate that SARS-CoV-2 has a much higher sensitivity to type I IFN
182 than the previously emergent SARS-CoV. This augmented type I IFN sensitivity is likely due to
183 changes in viral proteins between the two epidemic CoV strains. Moving forward, these data
184 could provide important insights for both the treatment of SARS-CoV-2 as well as developing
185 novel animal models of disease. In this ongoing outbreak, the results also highlight a distinction
186 between the highly related viruses and suggest insights from SARS-CoV must be verified for
187 SARS-CoV-2 infection and disease.

likya123
23/4/2020
11:18
He is quietly confident in that interview. Home Nebulisers are a great idea and it sounds like they are planning and examining how this will work. I would be totally amazed if the trial was not a success after that interview.
rafboy
23/4/2020
11:17
I got, they are at the forefront of the fight, they are going to make millions of treatments.and want to treat anyone with symptoms even at home.
bobaxe1
23/4/2020
11:11
This is the update we were all after surely! We knew that results can't be posted yet and you couldn't really get better at this stage. Clearly this video was done to answer the cries for Richard to update us. We can pump this board with our theories and positivity but an interview is from the company mouth. It's great imho
slinkyj
Chat Pages: Latest  199  198  197  196  195  194  193  192  191  190  189  188  Older

Your Recent History

Delayed Upgrade Clock